Format

Send to

Choose Destination
Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Author information

1
Scientific Direction, IRCCS-CROB, "Referral Cancer Centre of Basilicata", Rionero In Vulture (Pz), Italy.
2
Haematology, Department of Biomedicine and Prevention, "Tor Vergata" University, Rome, Italy.
3
Laboratory of Pre-clinical and Translational Research, IRCCS-CROB, "Referral Cancer Centre of Basilicata", Rionero In Vulture (Pz), Italy.
4
Haematology Clinic, Department of Clinic and Molecular Sciences, "Università Politecnica delle Marche", Ancona, Italy.
5
"Seràgnoli Institute of Haematology", University School of Medicine, Bologna, Italy.
6
Department of Haematology and Oncology, IRCCS AOU San Martino - IST, Genova, Italy.
7
Department of Emergency and Organ Transplantation, Haematology Section, University of Bari, Bari, Italy.
8
Onco-Haematology, "A. Tortora" Hospital, Pagani (Sa), Italy.
9
Department of Oncology and Haemato-Oncology, University of Milan and Haematology Unit, "Fondazione IRCCS Ca' Granda, Ospedale Maggiore" Policlinico, Milan, Italy.
10
Haematology Unit, "Di Miccoli" Hospital, Barletta, Italy.
11
Department of Onco-Haematology, IRCCS-CROB, "Referral Cancer Centre of Basilicata", Rionero in Vulture (Pz), Italy.
12
Pharmacy Unit, IRCCS-CROB, "Referral Cancer Centre of Basilicata", Rionero In Vulture (Pz), Italy.
13
Management Control Unit, IRCCS-CROB, "Referral Cancer Centre of Basilicata", Rionero In Vulture (Pz), Italy.
14
Department of Cellular Biotechnologies and Haematology, "La Sapienza" University, Rome, Italy.
15
Haematology Unit, "S. Eugenio" Hospital, Rome, Italy.
16
Haematology, University of Florence, AOU Careggi, Florence, Italy.
17
Haematology and Haematopoietic Stem Cell Transplant Centre, AORMN, Pesaro, Italy.
18
Haematology, "San Giovanni" Hospital, Rome, Italy.
19
FISM, Fondazione Italiana Sindromi Mielodisplastiche, Alessandria, Italy.

Abstract

Iron chelation is controversial in higher risk myelodysplastic syndromes (HR-MDS), outside the allogeneic transplant setting. We conducted a retrospective, multicentre study in 51 patients with transfusion-dependent, intermediate-to-very high risk MDS, according to the revised international prognostic scoring system, treated with the oral iron chelating agent deferasirox (DFX). Thirty-six patients (71%) received azacitidine concomitantly. DFX was given at a median dose of 1000 mg/day (range 375-2500 mg) for a median of 11 months (range 0·4-75). Eight patients (16%) showed grade 2-3 toxicities (renal or gastrointestinal), 4 of whom (8%) required drug interruption. Median ferritin levels decreased from 1709 μg/l at baseline to 1100 μg/l after 12 months of treatment (P = 0·02). Seventeen patients showed abnormal transaminase levels at baseline, which improved or normalized under DFX treatment in eight cases. One patient showed a remarkable haematological improvement. At a median follow up of 35·3 months, median overall survival was 37·5 months. The results of this first survey of DFX in HR-MDS are comparable, in terms of safety and efficacy, with those observed in lower-risk MDS. Though larger, prospective studies are required to demonstrate real clinical benefits, our data suggest that DFX is feasible and might be considered in a selected cohort of HR-MDS patients.

KEYWORDS:

International Prognostic Scoring System; deferasirox; iron chelation; myelodyslastic syndromes; revised-International Prognostic Scoring System

PMID:
28419408
DOI:
10.1111/bjh.14621
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center